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Abstract
Background: Transgelin is an actin-binding protein that promotes motility in normal cells. Although the role of
transgelin in cancer is controversial, a number of studies have shown that elevated levels correlate with aggressive
tumor behavior, advanced stage, and poor prognosis. Here we sought to determine the role of transgelin more
directly by determining whether experimental manipulation of transgelin levels in colorectal cancer (CRC) cells led
to changes in metastatic potential in vivo.
Methods: Isogenic CRC cell lines that differ in transgelin expression were characterized using in vitro assays of
growth and invasiveness and a mouse tail vein assay of experimental metastasis. Downstream effects of transgelin
overexpression were investigated by gene expression profiling and quantitative PCR.
Results: Stable overexpression of transgelin in RKO cells, which have low endogenous levels, led to increased
invasiveness, growth at low density, and growth in soft agar. Overexpression also led to an increase in the number
and size of lung metastases in the mouse tail vein injection model. Similarly, attenuation of transgelin expression in
HCT116 cells, which have high endogenous levels, decreased metastases in the same model. Investigation of mRNA
expression patterns showed that transgelin overexpression altered the levels of approximately 250 other transcripts,
with over-representation of genes that affect function of actin or other cytoskeletal proteins. Changes included
increases in HOOK1, SDCCAG8, ENAH/Mena, and TNS1 and decreases in EMB, BCL11B, and PTPRD.
Conclusions: Increases or decreases in transgelin levels have reciprocal effects on tumor cell behavior, with higher
expression promoting metastasis. Chronic overexpression influences steady-state levels of mRNAs for metastasis-related
genes.
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Background
Colorectal cancer (CRC) is a leading cause of cancer death
worldwide. Although early-stage, localized CRC is often
curable by surgical resection, some of these patients will
experience recurrent, metastatic disease. Currently, the
best predictor of risk is lymph node status. There is, how-
ever, considerable interest in identifying mechanistically
based, molecular markers to improve the ability to fore-
cast individual risk of disease recurrence. In a prior study,
we sought to identify such markers by proteomic analysis
of samples obtained by laser capture micro-dissection of
tumor tissue from node-negative and node-positive pa-
tients. Of these, transgelin, a 23 kDa actin binding protein,
ranked the highest in a statistical analysis [1].
Transgelin, also known as SM22α, is an abundant protein
in normal tissue [2]. It promotes podosome formation [3]
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and contributes to cell motility in response to injury or
inflammation [4, 5]. Transgelin knockout mice are viable
and fertile [6], but exhibit reduced smooth muscle contract-
ility [7, 8] and enhanced atherogenesis in a susceptible
background [9].
Perhaps because of its abundance, transgelin has been
frequently identified in proteomic profiling studies of
cancer. Early studies showed that expression is down-
regulated in early-stage cancer models [10, 11], leading to
the idea that transgelin is a tumor suppressor (reviewed in
[12]). However, proteomic studies of transgelin in human
cancers often indicate up-regulation in aggressive, late-
stage disease [13–16]. Several studies, although not all,
have shown a correlation between higher tumor transgelin
levels and aggressive behavior, advanced stage, or poor
prognosis [1, 17–21]. Consistent with this, various studies
have suggested an influence of transgelin on motility or
invasiveness in cell-based models [1, 22, 23]. A recent
review summarizes current understanding of transgelin in
normal tissue and malignancy [24].
One hypothesis that fits with most of the experimental
and clinical data is that transgelin is not a marker of
cancer per se, but rather a marker of metastatic potential
in advanced disease. One way that transgelin may influ-
ence metastasis is through direct interaction with cyto-
plasmic actin. There is also evidence that manipulation of
transgelin expression levels affects the expression of other
metastasis-related genes [1], suggesting a possible dual
mechanism of action.
Here, we adopt an approach based on comparison of
isogenic CRC cell populations that differ in transgelin
expression but are otherwise identical. We generated new
isogenic cell pairs, in which low transgelin-expressing
CRC cell lines were transfected with a transgelin cDNA
vector to create high-expressing derivatives. We also fur-
ther characterized a previously created isogenic cell pair,
in which high transgelin-expressing cells were stably
transfected with miRNA to attenuate transgelin expres-
sion. Overexpression in low-expressing cells and attenu-
ation in high-expressing cells had reciprocal effects on cell
behavior. In addition, comprehensive gene expression
profiling showed that increasing transgelin expression in a
low-expressing background led to changes in expression
of ~250 other mRNAs. Thus, experimental manipulation
of transgelin levels leads to wide-scale transcriptional
reprogramming.
Results
Establishment of a new transgelin overexpression cell
model
Previously, we described stable transfection of HCT116
and SW480 CRC cells with transgelin miRNA to create
two independent cell line pairs that differ in transgelin
protein and mRNA levels [1]. In both cases, lower
transgelin expression was associated with reduced motil-
ity, invasiveness, and resistance to anoikis. This pheno-
type could furthermore be reversed by transfection with
miRNA-resistant transgelin cDNA [1].
To extend and confirm the results of the transgelin
knockdown experiments, we tested a complementary
approach, creating a new isogenic cell line model in
which transgelin was overexpressed in CRC cells that
express endogenous transgelin at very low levels. We
transfected RKO CRC cells, in which endogenous transge-
lin is nearly undetectable, with a transgelin cDNA and
selected stable transfectants. After selection, virtually all
cells expressed a fluorescent transfection marker (Fig. 1a).
Immunoblotting showed high levels of transgelin protein
in cells that received the transgelin cDNA (RKOTAGLN),
whereas transgelin remained undetectable in cells that
received an empty control vector (RKOCTRL) (Fig. 1b).
Measurement of the relative levels of transgelin mRNA by
qPCR showed an increase of about 25-fold (Fig. 1c). The
overexpressed transgelin was distributed primarily in the
cytoplasm, as indicated by immunofluorescence staining
(Fig. 1d).
Effects of transgelin on invasiveness, clonogenicity, and
anchorage-independent growth
We investigated the phenotype of the newly created RKO
cell pair using in vitro assays. Transgelin overexpression
led to a 2 to 3-fold increase in invasiveness in a Transwell
assay (Fig. 2a). There was also an increase in the ability to
form colonies when plated at low density (Fig. 2b), and in
the number and size of colonies in a soft-agar growth
assay (Fig. 2c). Differences were highly significant in all
three assays (P < 0.01). Interestingly, transgelin expression
had essentially no effect on growth rate or cell cycle distri-
bution under standard cell culture conditions (Fig. 2d, e),
suggesting that transgelin expression primarily affects
behaviors relevant to metastasis (such as invasiveness,
clonogenicity, and anchorage-independent growth) rather
than growth per se.
Effect of transgelin on experimental metastasis
We next tested the behavior of isogenic cell pairs in a
model of experimental metastasis. RKOTAGLN or RKOCTRL
cells were injected via the tail vein into scid mice. We also
tested the behavior of previously described HCT 116 cells
stably transfected with a transgelin miRNA knockdown
vector (HCT116 TAGLN-KD) or with empty control vector
(HCT116CTRL) [1] in the same assay.
Tumor burden in each experimental group was mea-
sured by quantitative histologic analysis. Mice receiving
RKOTAGLN cells had more tumors than those receiving
RKOCTRL cells, and the tumors occupied a greater fraction
of the lung area (Fig. 3A). Similar results were seen with
HCT116CTRL and HCT116TAGLN-KD cells (Fig 3B). In both
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instances, the member of the isogenic pair that had higher
transgelin levels also had a greater tumor burden.
Although transgelin levels affected the number and size
of metastases, there were no consistent differences in
tumor histology (Fig. 3c, d). Immunostaining of HCT116-
derived tumors with anti-transgelin antibody showed that
tumors derived from the two cell populations retained
their respective transgelin phenotypes in vivo, with no
evidence of reversion (Fig. 3e). We did note that injection
with HCT116 TAGLN-KD cells resulted in an unexpected
incidence tumors near the injection site, instead of or in
addition to the lung metastases (6/10 with HCT116
TAGLN-KD versus 1/10 with HCT116CTRL). Tumors near
the injection site were not grossly evident in mice injected
with the RKO cells.
Gene expression profiling to identify downstream genes
Prior studies suggest that transgelin is capable of both
activating and repressing genes involved in tumor pro-
gression [1, 25, 26], although only a small number of
individual genes have been examined to date. To define
the full scope of transgelin-mediated gene regulation, we
performed comprehensive gene expression profiling on
RKOCTRL and RKOTAGLN cells using Affymetrix micro-
array technology.
Fig. 1 Establishment of transgelin-overexpressing RKO cell lines. a. Phase contrast images of unmodified RKO cells (RKOWT) and derivatives stably
transfected with empty vector (RKOCTRL) or with transgelin cDNA (RKOTAGLN). Inset, confocal fluorescence imaging showing the transfection marker,
EmGFP. b. Immunoblot analysis of total cell extracts from RKOCTRL or RKOTAGLN cells. c. Fold change in transgelin mRNA expression as determined by
real-time PCR analysis, normalized to GAPDH. Mean of three experiments, error bars denote standard deviation. P value determined by Student’s t-test.
d. Anti-transgelin immunostaining of RKOCTRL or RKOTAGLN cells. Cells were counterstained for DNA with DAPI; merged image is indicated. Scale
bar, 5 μm
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Based on criteria of adjusted P value <0.05 and a mini-
mum 2-fold change, 256 transcripts were significantly af-
fected, with approximately equal numbers of transcripts
increased and decreased (Fig. 4a). The most significantly
affected categories of genes were those involved in cytoskel-
etal and actin binding (Fig. 4b). Other categories that were
significantly affected included GTPase regulatory activities,
other enzyme regulatory activities and identical protein
binding (the ability to form homodimers or higher-order
multimers). Table 1 shows the ten most highly up-regulated
and ten most highly down-regulated genes. Interestingly,
prior studies implicate a number of these in metastasis or
cell motility (see Discussion).
Confirmation of gene expression changes by qPCR
To confirm the microarray results and investigate their
generality, we performed qPCR analysis to independently
determine mRNA levels for seven genes, chosen from
Table 1 based on cancer relevance (see Discussion for
details on the function of individual genes). We performed
the analysis using RNA from the RKO cells, which were
used for microarray, and also from an isogenic cell pair
derived from DLD-1 cells. Like RKO, DLD-1 is a widely
studied human CRC line with low endogenous transgelin
levels. Transgelin protein expression was undetectable by
immunoblotting in cells stably transfected with empty
control vector (DLD-1CTRL) and was greatly increased
following transfection with the transgelin expression vec-
tor (DLD-1TAGLN) (Fig. 5a).
The effect of chronic transgelin expression in RKO
and DLD-1 cells was strikingly similar and correlated
well with the microarray data (Fig. 5b and Additional file
1: Table S1). HOOK1, SDCCAG8, ENAH, and TNS1
were up-regulated in the presence of transgelin, with ef-
fect sizes ranging from 5-fold to more than one
hundred-fold. EMB, BCL11B, and PTPRD were down-
regulated 3- to 60-fold. The significance of these changes
in gene expression will be taken up in the Discussion; all
of the genes are related to the cytoskeleton or cancer,
and concordant regulation by transgelin in two inde-
pendent CRC lines suggests a general effect with a com-
mon mechanism.
Fig. 2 Effects of TAGLN overexpression on in vitro cell behavior. a. Invasiveness. Left, representative images showing invasion of RKOTAGLN and
RKOCTRL cells through Matrigel-coated Transwell filters, right, quantification of filter staining. b. Clonogenicity. Left, representative images of plates
seeded with RKOTAGLN or RKOCTRL cells, right, quantification of colony formation after 12 days. c. Growth in soft agar. Left, representative images
of colonies formed by RKOTAGLN and RKOCTRL cells, right, quantification colony formation after 17 days. d. Cell proliferation. Graph shows cell
count in replicate cultures of RKOTAGLN and RKOCTRL, counted daily for four days. Graphs in panels a-d show mean of three experiments. Error bars
denote standard deviation. e. Cell cycle distribution. Graph shows the percentage of RKOTAGLN and RKOCTRL cells in G0/G1, S, and G2/M phases of
the cell cycle. Data are mean of technical replicates from a single representative experiment. Error bars denote standard deviation. ** P < 0.01 by
Student’s t-test
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Discussion
Up-regulation of transgelin in low-expressing CRC cells
and down-regulation in high-expressing cells have
reciprocal effects
We characterized a new isogenic pair of high and low
transgelin-expressing cell populations. In contrast to our
previous study [1], where we knocked down expression
in two high expressing CRC lines, here we increased
transgelin expression in a low-expressing line. The over-
expressing variant showed gain of metastasis-related
behaviors in cell-based assays. Thus, overexpressing cells
showed increased ability to invade Matrigel, an increased
ability to form colonies when plated at low density, and
more and larger colonies in soft agar. The reciprocal
Fig. 3 Experimental metastasis assay. Mice were injected with test cells via the tail vein as described in Materials and Methods. a. Aperio Precision
image analysis on representative lung sections from animals injected with RKO cell derivatives. Twelve mice were used in each group. Left, total
tumor area per lung section; right, number of metastases per unit area of lung tissue. P value reflects results of a non-parametric Wilcoxon rank
sum test. b. Same analysis for HCT 116 cell derivatives. Ten mice were used in the HCT116CTRL group and 9 were used in the HCT116TAGLN-KD
group. Statistical analysis as in Panel a. c. Histology of representative tumor sections from mice injected with RKO cell derivatives. d. Same for mice
injected with HCT116CTRL derivatives. HCT116CTRL-derived tumor is a lung metastasis, HCT116TAGLN-KD-derived tumor arose near the injection site.
e. HCT116-derived tumors stained with anti-transgelin
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effects of up-regulation and down-regulation further
support the idea that transgelin levels are causally re-
lated to metastatic behavior.
Transgelin levels affect metastatic potential
Here, we show that experimental manipulation of trans-
gelin expression levels affects the metastatic potential of
CRC cells in vivo. In the experimental metastasis assay,
control HCT116 cells and RKO cells with stable overex-
pression of transgelin produced more and larger tumors
in the lung than their isogenic, low transgelin-expressing
counterparts. The widely used tail vein assay provides a
composite measure of the efficiency of sequential events
required for metastasis, including survival of isolated cells
in the bloodstream, extravasation into the lung, and subse-
quent colonization and proliferation to form observable
tumors [27]. Each of these steps has a parallel counterpart
that was previously measured in cell culture [1], including
resistance to anoikis, invasiveness in a Transwell assay, and
colony formation at low density, respectively. Although a
number of proteomic studies (but not all) have shown a
correlation between transgelin levels and advanced stage
disease and poor prognosis, data here imply a direct causal
relationship between transgelin levels and metastatic poten-
tial in vivo.
Mechanism of the transgelin effect
In normal cells and tissue, transgelin interacts directly
with the actin, influencing cell motility [3–5]. This
mechanism may apply in cancer cells as well. In addition
to direct interaction with actin, transgelin may also in-
fluence cell phenotype by affecting gene regulation. This
idea is based on transgelin’s partial nuclear localization,
its homology to transgelin 3, which has transcriptional
regulatory activity [28], and other evidence [1, 25, 26].
To address the influence of transgelin on gene regula-
tion in greater depth, we performed comprehensive gene
expression profiling comparing low- and high-expressing
RKO cells. Altering transgelin levels significantly affected
the expression of a set of ~250 other genes, with statis-
tical overrepresentation of cytoskeletal and actin-binding
proteins, together with various other regulatory genes.
The five most-highly upregulated genes in Table 1 are
connected with cancer, and in some cases specifically
Fig. 4 Effects of TAGLN overexpression on other genes. Gene expression profiling was performed using the Affymetrix platform. a. Hierarchical
clustering analysis of 256 genes that show significant expression differences (P < 0.05) and a minimum 2-fold change between RKOTAGLN and
RKOCTRL cells. Color represents relative gene expression on a log-transformed scale. b. Gene Ontology analysis for genes in Panel a
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with tumor metastasis. HOOK1 (up-regulated 96-fold)
interacts with microtubules and is up-regulated in breast
cancer [29]. SDCCAG8 (up-regulated 86-fold) organizes
the centrosome and is related to a colon cancer autoantigen
[30]. ENAH (up-regulated 18-fold), which is the mamma-
lian enabled homology and is also known as Mena, is a
transcriptional target of the wnt/beta-catenin pathway [31].
It facilitates cell invasion via phosphatidylinositol 3-kinase-
dependent local accumulation of actin filaments [32].
Increased ENAH/Mena expression levels correlate with
invasiveness of breast and salivary gland tumors[33, 34],
and are also seen in colorectal cancer and in polyps with
high grade dysplasia [35]. TNS1 (up-regulated 14-fold),
which is also known as Tensin 1, has actin cross-linking
activity and localizes to focal adhesions. Prior studies show
that increased expression of Tensin 1 correlates with tumor
cell migration [36, 37]. A sialyltransferase (ST8SIA4) has
been shown to promote metastatic dissemination in pan-
creatic cancer by interfering with E-cadherin dependent cell
adhesion [38].
Of the most highly down-regulated genes, EMB (down-
regulated 16-fold) is thought to mediate adhesion to the
extracellular matrix [39]. BCL11B (down regulated 12-fold)
is a tumor suppressor that is widely mutated in acute
lymphocytic leukemia [40] and has recently been shown to
be methylated, and thus likely down-regulated, in prostate
cancers [41]. PTPRD (down-regulated 11-fold), a tumor
suppressor that is frequently mutated in glioblastoma
[42, 43], Ewing’s sarcoma [44], lung cancer [45], cuta-
neous squamous cell carcinoma [46], and laryngeal
squamous cell carcinoma [47]. PTPRD has previously
been shown to suppress colon cancer cell migration
in cooperation with β-catenin/TCF signaling [48].
Based on an analysis of a more limited set of genes, we
had previously hypothesized that transgelin regulates the
epithelial-to-mesenchymal transition (EMT). In one cell
line, fibronectin and vimentin (mesenchymal markers)
and occludin (an epithelial marker) were affected. In an-
other, only fibronectin was affected. In the RKO model,
however, neither these nor other markers of EMT were
Table 1 Transcripts up- or down-regulated in transgelin cDNA-transfected RKO cells
Rank Symbol Gene name Fold up P
value
Function
1 HOOK1 Hook homolog 1 95.7 0.011 actin binding
2 SDCCAG8 serologically defined colon cancer antigen 8 85.8 0.023 microtubule organizing
center
3 ENAH enabled homolog 17.7 0.045 actin binding
4 TNS1 Tensin 1 14.3 0.014 actin binding
5 ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2, 8-sialyltransferase 4 13.2 0.047 sialyltransferase activity
6 ARHGAP29 Rho GTPase activating protein 29 13.0 0.046 GTPase activator activity
7 FBXL14 F-box and leucine-rich repeat protein 14 11.3 0.005 protein binding
8 ZNF704 zinc finger protein 704 10.5 0.020 zinc ion binding
9 CCDC141 coiled-coil domain containing 141 8.7 0.036 protein binding
10 SPECC1 sperm antigen with calponin homology and coiled-coil domains 1 8.2 0.020 cell adhesion





1 EMB embigin 15.9 0.005 cell adhesion
2 WIPF1 WAS/WASL interacting protein family, member 1 13.0 0.006 actin binding
3 BCL11B B-cell CLL/lymphoma 11B (zinc finger protein) 12.0 0.0004 nucleic acid binding
4 IL15 interleukin 15 11.3 0.010 signal transducer activity
5 PTPRD protein tyrosine phosphatase, receptor type, D 11.0 0.021 phosphoprotein
phosphatase
6 FRRS1 ferric-chelate reductase 1 10.4 0.004 ferric-chelate reductase
7 INSM1 insulinoma-associated 1 10.1 0.045 nucleic acid binding
8 PTGIS prostaglandin I2 (prostacyclin) synthase 9.8 0.006 monooxygenase
9 PDGFB platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis)
oncogene homolog)
9.8 0.004 PDGF receptor binding
10 POU3F1 POU class 3 home box 1 8.7 0.005 DNA binding
Gene expression profiling was performed on RKO cell populations that were stably transfected with empty control vector or with transgelin cDNA expression
vector. Experiment was performed using Affymetrix microarray technology as described in Methods. P values have been adjusted for multiple testing
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altered. Thus the effect of transgelin on EMT, if any, ap-
pears to be cell-line specific.
It remains unclear whether the effect of transgelin on
gene regulation occurs by a direct or indirect mechanism.
Transgelin localized partially in the nucleus of the CRC
cells; it shares 85 % similarity to TAGLN3, which is be-
lieved to be a transcriptional regulator [28]; Bioinformatic
analysis using the DP-bind Web server (http://lcg.rit.alba-
ny.edu/dp-bind) identified several segments of transgelin
as having high DNA-binding potential (data not shown);
studies also suggests that nuclear actin-binding proteins
participate widely in the transcription processes (reviewed
in [49]). We were, however, unable, to detect direct associ-
ation of transgelin with RNA polymerase II or chromatin
(HMZ, YYF, and YL, unpublished results), which suggests
that transgelin most likely works indirectly, through inter-
action with other transcriptional regulatory proteins,
rather than by direct interaction with the polymerase or
template.
Transgelin in the context of human CRC
The original impetus for the studies reported here was to
identify biomarkers that could be quantified at the time of
surgical resection and used to predict metastatic risk.
Transgelin is abundant in normal tissue and is not a marker
of cancer per se. In our work, however, it discriminated well
between node-positive and node-negative CRC specimens
[1].
Evaluation of potential biomarkers should ideally in-
clude evidence that they influence the biological process
of interest; that is, adding or subtracting transgelin in a
given context influences phenotypic behaviors associated
with metastatic risk. Combining the results presented
with those of a previous study [1], we have created four
isogenic pairs (HCT116, SW480, RKO, and DLD-1),
three have been characterized with respect to in vitro
phenotypes (HCT116, SW480, and RKO) and two
(HCT116 and RKO) have been characterized in an ani-
mal model of experimental metastasis. The combined
results are consistent with a contribution of transgelin to
metastatic potential.
Human CRC is characterized by genomic instability and
variability, and caution is warranted in generalizing from
results with individual cell lines. However, laboratory find-
ings provide a rationale for continuing to explore the po-
tential of transgelin, perhaps in conjunction with other
biomarkers, as a predictor of individual risk. As noted
earlier, proteomic studies of human cancer are not in uni-
versal agreement with respect to the role of transgelin,
and it will be important to identify the root cause of the
discrepancies, which could relate either to different patient
populations or to technical factors. Separately, the finding
Fig. 5 Expression of selected mRNAs determined by qPCR in RKO and DLD-1 cell derivatives. a. Immunoblot analysis of total cell extracts from
DLD-1 derivatives stably transfected with empty vector (DLD-1CTRL) or with transgelin cDNA (DLD-1TAGLN). b. Real-time RT-PCR analysis for the
levels of mRNA in RKO and DLD-1 cells of selected top-ranked differentially expressed genes identified by the cDNA microarray. Gene expression
was normalized to GAPDH. Error bars denote standard deviation. All changes were significant (P < 0.05 by Student’s t-test) except for the one
result indicated (#)
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that a number of gene products are co-regulated with
transgelin suggests that they may be attractive targets for
drug therapy in advanced CRC.
Conclusions
The results support a hypothesis that transgelin expres-
sion levels influence metastatic potential in CRC cell
lines, and this may occur in part due to altered expres-
sion of downstream target genes that affect cell motility.
Methods
Isogenic cell line pairs
RKO and DLD-1 colon carcinoma cells were obtained from
ATCC (Manassas, VA; CRL-2577 or CRL-221 respectively).
Cells were transfected with pcDNA6.2/EmGFP-Bsd/V5-
DEST or pcDNA6.2/EmGFP-Bsd/V5-TAGLN-mut vectors;
the latter was generated using pDONR221-TAGLN-mut
from a previous study[1] by an LR recombination). Stable
transfectants were selected in medium containing 25 μg/ml
blasticidin (Invitrogen, Carlsbad, CA). Immunoblot analysis
was performed using anti-transgelin IgG or anti-GAPDH
IgG1 (Abcam, Cambridge, MA) with ECL substrate for de-
tection (Thermo Fisher Scientific, Rockford, IL). Immuno-
fluorescence was performed on paraformaldehyde-fixed
cells as described [1]. For qPCR, total RNA was extracted
using Trizol (Invitrogen), cDNA was prepared, and qPCR
was performed using primers in Additional file 2: Table S2.
Reactions were performed using a SYBR Green PCR kit
(Qiagen, Germantown, MD) and a LightCycler 480 instru-
ment (Roche Applied Science, Indianapolis, IN).
Creation and characterization of HCT116CTRL and
HCT116TAGLN-KD populations has been described [1]. In
brief, cells were transfected with plasmid expressing an
artificial microRNA (Invitrogen, Hmi416875) or with
control vector and drug selection was applied to obtain
cell populations that differed by about five-fold in trans-
gelin expression levels.
Transwell invasion assay
Cell invasion assays were performed as described [1, 50]
using a Transwell permeable support (8.0 μm pore size in
6-well format, Corning Life Sciences, Corning, NY). Filters
were coated with 650 μg/ml Matrigel (BD Biosciences,
Sparks, MD) according to the manufacturer’s protocol.
Cells were harvested and resuspended in serum-free
medium, and 2 × 105 cells were applied onto the upper
chamber of the Transwell apparatus. The bottom chamber
contained 0.6 ml of medium supplemented with 10 % fetal
bovine serum. Cells were incubated for 48 hours. Cells
that did not migrate were removed by cotton swabbing.
Remaining cells were fixed with 4 % formaldehyde for
20 minutes at room temperature and stained with 0.1 %
crystal violet for 15 minutes, also at room temperature.
The stained cells were extracted with 10 % acetic acid, and
the absorbance at 595 nm was measured.
Clonogenic survival assay
Cells were plated at 2 × 102 per 60 mm dish and incubated
with complete growth medium for 12 days. Colonies were
fixed and stained with staining buffer (0.1 % crystal violet,
4 % formaldehyde) for 30 minutes at room temperature.
Soft agar colony formation assay
Eagle’s MEM supplemented with 20 % fetal bovine serum,
was adjusted to 0.6 % agar and distributed in a 6-well plate
to form a base layer. Cells (2.5 × 102 cells per well) were
suspended in the same medium containing 0.35 % agar
and the suspension was dispensed to each well. Cultures
were fed twice weekly with an overlay of complete
medium. After 17 days colonies of 100 or more cells were
counted.
Cell proliferation assay
Replicate cultures were seeded in 6-well dishes (1 × 105
cells/well). Triplicate samples of each cell population
were harvested and counted daily for four days.
Cell cycle analysis
For cell cycle analysis, 5 × 105 cells were fixed with 70 %
ethanol overnight at 4 °C, washed twice with PBS, and
incubated with 50 μg RNase (Sigma-Aldrich, USA) and
9 μg propidium iodide (Invitrogen, USA) for 30 minutes
at 4 °C in the dark. DNA content was analyzed using a
FACSCalibur flow cytometer (Becton Dickinson, USA).
Tail vein assay of experimental metastasis
For the tail vein assay [51], 2 × 106 cells were suspended in
0.15 ml of Hank’s solution, filtered to obtain a single-cell
suspension, and injected using a 28-gauge needle into a
tail vein of six-week-old CB.17 scid mice. Mice were sacri-
ficed after 6–8 weeks or when they exhibited signs of
disease (weight loss and decreased grooming). Animals
were necropsied and lungs and any other organs that
showed gross tumors were fixed, paraffin embedded, and
stained with hematoxylin and eosin for examination by a
pathologist. The number of tumors in lung, heart, kidney,
rib, back (near the injection site), leg, and foot was scored.
Representative lung tissue sections were imaged using an
Aperio Scanscope eSlide capture device and analyzed
using Aperio Precision image analysis software.
cDNA microarray analysis
Gene expression profiling was performed using an Affyme-
trix Gene Chip Human Genome U133 Plus 2.0 Array,
which contains 54,000 probe sets representing 38,500 well-
characterized human genes (Affymetrix, Santa Clara, CA).
Total RNA was isolated from triplicate cultures using the
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TRIzol method. After passing a quality control measure-
ment, RNA was amplified and labeled using the Affymetrix
3’ IVT Express kit and hybridized to the array for 16 hours.
This was followed by washing and staining using the
Affymetrix fluidics station 450. Arrays were scanned using
an Affymetrix 3000 7G plus instrument. AGCC software
was used to generate .cel files. CHP files were generated
with the mas5 method using the Affymetrix Expression
Console. Data were imported into the Agilent Gene Spring
GX software for further analysis. Statistical significance of
inter-group differences was evaluated by a t-test with
Bonferroni correction. Unsupervised hierarchical clustering
analysis was performed using Spotfire 5.0 software (TIBCO,
Somerville, MA). The row dendrogram was generated
using Ward’s clustering method with a half square Euclid-
ean distance measure. The column dendrogram was gener-
ated using the single linkage clustering method and a
Euclidean distance measure. Gene ontology analysis was
based on David 6.7 [52, 53] (http://david.abcc.ncifcrf.gov).
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